| Literature DB >> 34239233 |
R Parvati1, M V Subbalaxmi2, R Srikanth1, P Sajani1, R V Koteswara Rao1.
Abstract
Introduction This is a retrospective therapeutic series of eight cases of facial mucormycosis treated over a 15-year period to determine the safety of simultaneous debridement and free-flap reconstruction in facial mucormycosis. Methods Surgical debridement was done for three cases that presented acutely with systemic manifestations (group 1) and five cases that presented in the subacute phase without systemic manifestations (group 2). The debridement involved total maxillectomy with orbital exenteration in three cases, total maxillectomy with orbital preservation in two, and subtotal maxillectomy in three cases. A total of seven out of eight patients underwent reconstruction with free flap for defect closure; in one patient, only primary closure of mucosa was done. Results The mean follow-up was 20.5 months. Two patients with acute disease, where reconstruction was done, died in the postop period (on the 27th and 6th day post reconstruction, respectively) due to continuing infection and septic shock. One of the three (group 1), who presented acutely and underwent debridement alone, survived. Four of five patients in group 2 underwent successful free-flap reconstruction. The patient with free-flap loss was salvaged with an extracorporeal radial forearm flap. All except one patient had a soft-tissue free-flap reconstruction. Three of the six living patients reported for secondary surgery. The inability to achieve clear nonnecrotic surgical margins due to extensive disease was the reason for mortality in two patients in group 1. There was no mortality in any of the group 2 patients, even when debridement and free-flap coverage was done simultaneously. Conclusion Simultaneous debridement and free flap can be successfully implemented in select cases of facial mucormycosis. Association of Plastic Surgeons of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Keywords: facial mucormycosis; fungus; maxillectomy; microvascular flap; mucormycosis; reconstruction
Year: 2021 PMID: 34239233 PMCID: PMC8257306 DOI: 10.1055/s-0041-1731961
Source DB: PubMed Journal: Indian J Plast Surg ISSN: 0970-0358
Fig. 1Preop photos showing ulcer over the cheek and right orbital cellulitis.
Fig. 2( A ) Defect following maxillectomy and exenteration; ( B ) excised necrotic tissues; ( C ) harvested anterolateral thigh (ALT) flap with fascial extension; ( D ) intraoral view of skin paddle inset over hemipalate.
Fig. 3Postop photos at 15 days with nasopharyngeal airway to prevent nasal stenosis.
Demography and clinical presentation in individual cases
| Case No | Date of surgery | Age | Sex | Predisposing factor | Diagnostic history | Presentation | Initial treatment |
|---|---|---|---|---|---|---|---|
| Abbreviation: CNS, central nervous system. | |||||||
| 1 | 8–2–2002 | 48 | M | Diabetes, hypertension | Biopsy | Acute presentation with orbital cellulitis, orbital apex syndrome and impending CNS spread | Amphotericin 32 days before debridement |
| 2 | 19–3–2003 | 51 | M | Diabetes | KOH mount | Acute presentation with orbital cellulitis, ophthalmoplegia and impending CNS spread | Amphotericin 24 days before debridement |
| 3 | 13–12–2004 | 21 | F | Gestation-induced diabetes | Biopsy | Eschar over palate and ulcer anterior wall maxilla; no systemic manifestations | Amphotericin 21 days a |
| 4 | 14–9–2007 | 27 | M | Newly diagnosed diabetes | KOH mount | Eschar over palate and ulcer anterior wall maxilla; orbital swelling; no systemic manifestations | Amphotericin 14 days a |
| 5 | 1–2–2008 | 38 | M | Diabetes, hypertension | KOH mount | Naso-oroantral fistula; no vision in eye due to central retinal artery thrombosis; quiescent orbit tissues; no systemic manifestations of fungal infection | Amphotericin 37 days a |
| 6 | 11–2–2014 | 32 | M | Diabetes | KOH mount | Naso-oroantral fistula; no systemic manifestations of fungal infection | Amphotericin 40 days |
| 7 | 5–6–2017 | 16 | M | Insulin-dependent diabetes | Biopsy | Eschar over anterior maxillary wall and infraorbital rim; no systemic manifestations of fungal infection | Amphotericin 42 days |
| 8 | 24–11–2017 | 50 | M | Diabetes, hypertension | Biopsy | Acute presentation with systemic symptoms and necrotic patch over upper central alveolus and palate; systemic manifestations of infection present | Amphotericin 28 days before debridement |
Fig. 4Preop photos of acute presentation with orbital cellulitis and eschar over the palate.
Fig. 5( A ) Maxillectomy exenteration defect; ( B ) debrided necrotic tissues; ( C ) skin paddle of gracilis used for palatal mucosa inset; ( D ) completed closure of Weber–Ferguson incision.
Fig. 6( A ) Necrotic eschar over the central maxillary alveolus and palate; ( B ) necrosis over the mandibular alveolus.
Fig. 7( A ) Asterisk shows necrotic upper alveolus and contiguous pyriform aperture; ( B ) necrotic bone specimen removed.
Fig. 8Photos showing completion of debridement, mucosal closure primarily, and skin closure of bilateral Weber–Ferguson incisions.
Fig. 9Preop photos showing necrotic palatal bone and naso-oroantral fistula.
Fig. 10( A ) Harvested rectus abdominis flap with skin paddle; ( B ) inset flap prior to skin closure; ( C ) intraoral view of paddle inset on hemipalate.
Fig. 11Follow-up photos showing acceptable contour prior to secondary correction surgery.
Fig. 12Preop photos showing oronasal fistula, necrotic alveolus, and nasal dorsal collapse.
Excisional defect and reconstructive method in individual cases
| Case No | Areas afflicted | Excision and defect | Reconstruction | Recipient pedicles | Remarks |
|---|---|---|---|---|---|
| Abbreviations: ALT, anterolateral thigh; CRA, central retinal artery; EJV, external jugular vein. | |||||
| 1 | Eye, ipsilateral maxilla and palate | Maxillectomy and orbital exenteration | Gracilis with skin paddle | Facial artery and 1 venae comitantes | Septic shock death 27th day postreconstruction |
| 2 | Eye, ipsilateral maxilla and palate | Maxillectomy and orbital exenteration | Gracilis with skin paddle | Facial artery and 1 venae comitantes | Septic shock death 6th day postreconstruction |
| 3 | Infraorbital rim and anterolateral maxilla full thickness cheek defect ipsilateral hard palate | Maxillectomy and orbital preservation | ALT flap | Facial artery and EJV | Flap loss due to venous congestion 3rd postop day; flap debridement done; at 3 weeks extracorporeal folded radial forearm flap done. Detachment and inset after 23 days |
| 4 | Anterolateral wall maxilla, hard palate and orbit | Maxillectomy and orbital exenteration | ALT flap | Facial artery and 1 venae comitantes | Complete flap survival; amphotericin for 15 days postop. Lost to follow-up after that time. |
| 5 | Allergic rhinitis/lateral rhinotomy and oronasal fistula | Maxillectomy and orbital preservation | Rectus abdominis myocutaneous flap | Facial artery and 2 venae comitantes | Complete flap survival; one secondary skin paddle reduction 4 months later; follow-up of 22 months |
| 6 | Central portion middle third of face; nasal bones, maxillary alveolus, oronasal fistula | Subtotal maxillectomy a | Fibula osteocutaneous flap | Facial artery and 2 venae comitantes | Complete flap survival; secondary skin paddle thinning and augmentation rhinoplasty with bone graft; follow-up for 50 months |
| 7 | Superomedial maxilla and orbital floor; palate unaffected | Subtotal maxillectomy b | Gracilis and skin graft | Facial artery and 1 venae comitantes | Complete flap survival; partial skin graft loss with secondary healing;15 months follow-up |
| 8 | Central upper maxilla, mandibular alveolus, lower third of the nose | Subtotal maxillectomy c | No reconstruction done | – | 6 month follow up |